Clinical applications of the CellSearch platform in cancer patients

Sabine Riethdorf; Linda O'Flaherty; Claudia Hille; Klaus Pantel

doi:10.1016/j.addr.2018.01.011

Clinical applications of the CellSearch platform in cancer patients

Standard

Clinical applications of the CellSearch platform in cancer patients. / Riethdorf, Sabine; O'Flaherty, Linda; Hille, Claudia ; Pantel, Klaus.

in: ADV DRUG DELIVER REV, Jahrgang 125, 01.02.2018, S. 102-121.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Riethdorf, S, O'Flaherty, L, Hille, C & Pantel, K 2018, 'Clinical applications of the CellSearch platform in cancer patients', ADV DRUG DELIVER REV, Jg. 125, S. 102-121. https://doi.org/10.1016/j.addr.2018.01.011

APA

Riethdorf, S., O'Flaherty, L., Hille, C., & Pantel, K. (2018). Clinical applications of the CellSearch platform in cancer patients. ADV DRUG DELIVER REV, 125, 102-121. https://doi.org/10.1016/j.addr.2018.01.011

Vancouver

Riethdorf S, O'Flaherty L, Hille C , Pantel K. Clinical applications of the CellSearch platform in cancer patients. ADV DRUG DELIVER REV. 2018 Feb 1;125:102-121. https://doi.org/10.1016/j.addr.2018.01.011

Bibtex

@article{6920fa13d397488e949d11292acaadf3,

title = "Clinical applications of the CellSearch platform in cancer patients",

abstract = "The CellSearch{\textregistered} system (CS) enables standardized enrichment and enumeration of circulating tumor cells (CTCs) that are repeatedly assessable via non-invasive {"}liquid biopsy{"}. While the association of CTCs with poor clinical outcome for cancer patients has clearly been demonstrated in numerous clinical studies, utilizing CTCs for the identification of therapeutic targets, stratification of patients for targeted therapies and uncovering mechanisms of resistance is still under investigation. Here, we comprehensively review the current benefits and drawbacks of clinical CTC analyses for patients with metastatic and non-metastatic tumors. Furthermore, the review focuses on approaches beyond CTC enumeration that aim to uncover therapeutically relevant antigens, genomic aberrations, transcriptional profiles and epigenetic alterations of CTCs at a single cell level. This characterization of CTCs may shed light on the heterogeneity and genomic landscapes of malignant tumors, an understanding of which is highly important for the development of new therapeutic strategies.",

keywords = "Journal Article, Review",

author = "Sabine Riethdorf and Linda O'Flaherty and Claudia Hille and Klaus Pantel",

year = "2018",

month = feb,

day = "1",

doi = "10.1016/j.addr.2018.01.011",

language = "English",

volume = "125",

pages = "102--121",

journal = "ADV DRUG DELIVER REV",

issn = "0169-409X",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Clinical applications of the CellSearch platform in cancer patients

AU - Riethdorf, Sabine

AU - O'Flaherty, Linda

AU - Hille, Claudia

AU - Pantel, Klaus

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The CellSearch® system (CS) enables standardized enrichment and enumeration of circulating tumor cells (CTCs) that are repeatedly assessable via non-invasive "liquid biopsy". While the association of CTCs with poor clinical outcome for cancer patients has clearly been demonstrated in numerous clinical studies, utilizing CTCs for the identification of therapeutic targets, stratification of patients for targeted therapies and uncovering mechanisms of resistance is still under investigation. Here, we comprehensively review the current benefits and drawbacks of clinical CTC analyses for patients with metastatic and non-metastatic tumors. Furthermore, the review focuses on approaches beyond CTC enumeration that aim to uncover therapeutically relevant antigens, genomic aberrations, transcriptional profiles and epigenetic alterations of CTCs at a single cell level. This characterization of CTCs may shed light on the heterogeneity and genomic landscapes of malignant tumors, an understanding of which is highly important for the development of new therapeutic strategies.

AB - The CellSearch® system (CS) enables standardized enrichment and enumeration of circulating tumor cells (CTCs) that are repeatedly assessable via non-invasive "liquid biopsy". While the association of CTCs with poor clinical outcome for cancer patients has clearly been demonstrated in numerous clinical studies, utilizing CTCs for the identification of therapeutic targets, stratification of patients for targeted therapies and uncovering mechanisms of resistance is still under investigation. Here, we comprehensively review the current benefits and drawbacks of clinical CTC analyses for patients with metastatic and non-metastatic tumors. Furthermore, the review focuses on approaches beyond CTC enumeration that aim to uncover therapeutically relevant antigens, genomic aberrations, transcriptional profiles and epigenetic alterations of CTCs at a single cell level. This characterization of CTCs may shed light on the heterogeneity and genomic landscapes of malignant tumors, an understanding of which is highly important for the development of new therapeutic strategies.

KW - Journal Article

KW - Review

U2 - 10.1016/j.addr.2018.01.011

DO - 10.1016/j.addr.2018.01.011

M3 - SCORING: Review article

C2 - 29355669

VL - 125

SP - 102

EP - 121

JO - ADV DRUG DELIVER REV

JF - ADV DRUG DELIVER REV

SN - 0169-409X

ER -